Dr. Ming Yin is the Deputy General Manager of Beijing Vitalstar Biotechnology Co., Ltd., responsible for product development, technical services, marketing, and sales. With extensive experience in research, project management, and commercialization, she has led the development and application of innovative humanized animal models in China. Dr. Yin is actively involved in the experimental animal industry and biodiversity conservation. She serves on multiple expert committees and was selected for the global Homeward Bound Project in 2020, contributing to scientific leadership and sustainability efforts through an Antarctic expedition in 2023.

Dr. Miao Zhenchuan R&D Director of Beijing VitalStar Biotechnology Co., Ltd. He got Ph.D. from the Institute of Zoology, Chinese Academy of Sciences, and had done research work as postdoctoral fellow on single-cell analysis technology of stem cells at York University in Canada and on hematopoietic stem cell differentiation at the College of Life Sciences, Peking University. He has been engaged in development of humanized animal models for over twenty years. Dr. Miao had been involved in the Global Health Challenge Project funded by the Bill & Melinda Gates Foundation, and leaded his team to successfully create NOD-scid IL2rgnull (NPG) mouse, the first highly immunodeficient mouse strain in China, and establish humanized immune system mouse models based on NPG. Since then, they have developed many next generation NPG mouse strains that have been further modified for being adaptive to various usages. Miao’s team also optimized the protocol for preparing humanized liver mouse models using immunodeficient and inducible liver damage mouse URG and obtained high chimeric rate humanized liver mice. Up to date, they have established tens of thousands of humanized immune system mouse models and humanized liver mouse models for biomedicine research. The series of tumor and liver disease animal models prepared by Dr. Miao and his team have been widely recognized and used in both academia and industry.

Dr.Weifeng Yang Director of product service department of Beijing Vitalstar Biotechnology Co., LTD., Doctor of clinical veterinary medicine of Northwest A&F University, postdoctoral fellow of life sciences of Peking University, engaged in research and development of small molecule induced pluripotent stem cells and genetically modified animal models. Currently, I am responsible for the research and development of liver disease models, including hepatitis B, NASH/MASH and liver cancer models, pharmacological and pharmacodynamic experiments, and NMPA on-site verification of new drugs. According to different etiologies of liver fibrosis, such as hepatic toxic injury (NASH/MASH, HBV/HCV, ASH, etc.) and cholestatic injury, the corresponding preclinical rodent models were optimized. Including: (1) Hu-URG® mouse population screening, determination of human primary hepatocyte viability and optimization of hepatocyte transplantation process of mice with controllable liver injury humanized liver, achieving a human liver chimerism rate of up to 95% and a reconstruction success rate of up to 100%. (2) The first HBV-Tg transgenic mice with high expression of hepatitis B virology index in China had serum HBV-DNA of 107~108 IU/mL and HBsAg of 104 IU/mL. (3) Diet induced DIO and MASH models; gene humanized MASH and liver humanized MASH models. (4) Humanized MASH-HCC models that are more closely related to human clinical complex disease characteristics:① Hu-URG®/ NPG-MASH-HCC model; ②HBV-MASH-HCC model. Papers from participating projects have been published in journals such as Cell, Science, Cell stem cell, and Stem cells.

Dr.Liu Shujun Director of the GEMS Department at Beijing Vitalstar Biotechnology Co., Ltd., Ph.D., graduated from the College of Life Sciences at Peking University. She primarily focuses on the genenration of genetically engineered mouse or rat animal models, having created over a hundred strains of genetically edited mice/rats, including gene knockouts, conditional gene knockouts, point mutations, random transgenics, and various other types of mice/rats models. She has published 6 first-author SCI papers and applied for 4 national invention patents. Since 2021, he has been working at Beijing Vitalstar Biotechnology Co., Ltd. as the Director of the GEMS Department, specializing in the research and development of genetically modified animal models.